The estimated Net Worth of Christopher J Coughlin is at least 3.6 百万$ dollars as of 29 April 2022. Mr. Coughlin owns over 12,000 units of Alexion Pharmaceuticals stock worth over 2,904,381$ and over the last 20 years he sold ALXN stock worth over 67,387$. In addition, he makes 630,108$ as Independent Director at Alexion Pharmaceuticals.
Christopher has made over 7 trades of the Alexion Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 878 units of ALXN stock worth 67,387$ on 14 May 2024.
The largest trade he's ever made was buying 12,000 units of Alexion Pharmaceuticals stock on 29 April 2022 worth over 976,440$. On average, Christopher trades about 824 units every 47 days since 2004. As of 29 April 2022 he still owns at least 15,864 units of Alexion Pharmaceuticals stock.
You can see the complete history of Mr. Coughlin stock trades at the bottom of the page.
Christopher J. Coughlin serves as Independent Director of the Company. Mr. Coughlin served as Advisor to the Chairman and CEO of Tyco International Ltd., a global provider of diversified products, services and industries, from 2010 to 2012, and as Executive Vice President and Chief Financial Officer of Tyco from 2005 to 2010, during a period of significant international growth and restructuring. Mr. Coughlin previously served at the Interpublic Group of Companies, Inc. as Executive Vice President, Chief Operating Officer from 2003 to 2004. From 1998 to 2003, he served as Executive Vice President and Chief Financial Officer of Pharmacia Corporation. From 1997 to1998, he was President, International at Nabisco Group Holdings and from 1996 to 1997 was Executive Vice President and Chief Financial Officer of Nabisco. From 1981 to 1996, Mr. Coughlin held various positions with Sterling Winthrop Incorporated, including Chief Financial Officer. Mr. Coughlin received a BS in accounting from Boston College. Mr. Coughlin is an audit committee financial expert.
As the Independent Director of Alexion Pharmaceuticals, the total compensation of Christopher Coughlin at Alexion Pharmaceuticals is 630,108$. There are 8 executives at Alexion Pharmaceuticals getting paid more, with Ludwig Hantson having the highest compensation of 18,948,000$.
Christopher Coughlin is 67, he's been the Independent Director of Alexion Pharmaceuticals since 2014. There are 1 older and 17 younger executives at Alexion Pharmaceuticals. The oldest executive at Alexion Pharmaceuticals Inc. is John Mollen, 69, who is the Independent Director.
Christopher's mailing address filed with the SEC is 7700, Forsyth Boulevard, Clayton, Saint Louis County, Missouri, 63105, United States.
Over the last 21 years, insiders at Alexion Pharmaceuticals have traded over 451,742,532$ worth of Alexion Pharmaceuticals stock and bought 2,576,434 units worth 277,855,180$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、Leonard Bell、Paul A Friedman. On average, Alexion Pharmaceuticals executives and independent directors trade stock every 9 days with the average trade being worth of 3,460,578$. The most recent stock trade was executed by Daniel Bazarko on 17 December 2020, trading 24,066 units of ALXN stock currently worth 2,816,685$.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticals executives and other stock owners filed with the SEC include: